Scope and claims analysis for U.S. Patent 11,020,361: intranasal metoclopramide citrate for gastroparesis

U.S. Patent 11,020,361 claims a specific route (intranasal) and a specific metoclopramide product profile (delivering ~15 mg, with citrate at ≥10 mM, and optional excipient and parameter limitations including buffer selection, benzalkonium chloride, benzyl alcohol, pH, osmolality). The claim set is drafted as a method-of-treatment claim that is structurally tethered to a defined formulation boundary, with several dependent claims narrowing into preferred preservative/buffer/pH/osmolality windows and dosing-device details (intranasal spray; two sprays). Overall, the independent claim is moderately narrow on “intranasal + citrate ≥10 mM + ~15 mg delivered” and becomes tighter as dependent claims add excipient identity and numeric ranges.

How broad are the claims in US Patent 11,020,361 and what exactly must an accused product do?

Core answer: To fall within claim 1, a method must (i) treat gastroparesis, (ii) use intranasal administration of metoclopramide composition delivering about 15 mg metoclopramide (or salt), and (iii) use a composition comprising citrate at ≥10 millimolar, with intranasal administration being effective for gastroparesis.

Claim 1 element-by-element (tethered formulation boundary)

Claim 1 requires all elements:

Treating target indication: gastroparesis in a patient.
Route: intranasal administration.
Drug identity: metoclopramide (or pharmaceutically acceptable salt).
Dose delivery: “effective to deliver about 15 mg of metoclopramide.”
- The phrase “about 15 mg” introduces flexibility (not a hard single value), but it is still a numerical anchor.
Formulation requirement: composition comprises citrate in concentration ≥ about 10 mM.
- This is the key formulation discriminator in the independent claim.
Functional linkage: intranasal administering is effective to treat gastroparesis.

What claim 1 does not require

It does not require a particular buffer species in claim 1 (that is left for dependent claim 2 via “further comprises a buffer”).
It does not require a specific preservative system in claim 1 (benzalkonium chloride is only in claim 3/4).
It does not require pH/osmolality/buffer identity/numeric pH or osmolality in claim 1.
It does not require spray dosing (only claim 15/16).
It does not require patient being human (claim 17).

Practical infringement logic

Because claim 1 is a method claim with formulation parameters as limitations, an accused product typically must be close on:

Route (intranasal rather than oral/IV/IM),
Dose magnitude (about 15 mg),
Citrate level (≥10 mM),
and the method’s therapeutic purpose (gastroparesis).

If a generic or reformulated competitor changes any of those anchor parameters materially (especially citrate ≥10 mM and the ~15 mg delivered dose), it creates design-around leverage.

Which dependent claims narrow the scope most and how do those numeric windows constrain design-arounds?

Core answer: The tightest dependent claim constraints are the preservative concentration windows (benzalkonium chloride), pH > ~4.5, benzyl alcohol concentration, and osmolality 500 to 1400 mOsm/kg, plus specific buffer lists and intranasal spray administration details.

Claim 2: buffer addition (identity not limited in claim 2)

Dependent on claim 1.
Adds: composition further comprises a buffer.
The “buffer” limitation is broad in claim 2 until claim 8 narrows buffer selection.

Claim 3/4: benzalkonium chloride (numeric preservative window)

Claim 3: further comprises benzalkonium chloride.
Claim 4: benzalkonium chloride concentration from 0.005% (w/v) to 0.05% (w/v).
- This establishes a quantifiable preservative boundary.
- A product using benzalkonium chloride outside this window risks avoiding claims 3/4 (but may still infringe claim 1 depending on other elements).

Claim 5: pH constraint

Composition has a pH above about 4.5.
- This creates another quantitative/threshold limitation for dependent coverage.

Claim 6/13: benzyl alcohol (numeric window)

Claim 6: composition further comprises benzyl alcohol.
Claim 13: benzyl alcohol concentration from 0.01% (w/v) to 0.8% (w/v).
- Another numeric window for design around by changing preservative system and/or concentration.

Claim 7: osmolality window

Osmolality from about 500 to 1400 mOsm/kg.
- Competitors can alter tonicity, but must do so without upsetting other limitations (citrate level, pH, buffer choice, dose delivery).

Claim 8/9/10: buffer identity (large genus list; citrate/acetate examples)

Claim 8: buffer selected from a long list including, among others:
citric acid/phosphate, acetate, … citrate, … phosphate, … sodium acetate (via claim 9), sodium citrate (via claim 10), and many biological buffer systems (e.g., HEPES-family, MOPS/PIPES/TES, etc.).
Claim 9: buffer comprises sodium acetate.
Claim 10: buffer comprises sodium citrate.

Two consequences:

The long buffer list in claim 8 is broad at the genus level (many salts/buffers), but still functions as a closed selection for dependent claims 8–10.
Claim 9 and 10 carve out specific buffer salt embodiments.

Claim 11/12: disorder list (indication tether)

Claim 11: patient has a disorder treatable with metoclopramide.
Claim 12: selected from gastroparesis, emesis, delayed emesis, nausea.
- Because independent claim 1 already requires gastroparesis, claims 11/12 mostly add alternative context limiting “disorder” to known metoclopramide-treatable conditions.
- The presence of other nausea/emesis labels in claim 12 can matter for scenario-based infringement arguments (e.g., if the patent holder asserts broader intranasal metoclopramide treatment beyond gastroparesis).

Claim 14: optional formulation excipients

Adds at least one member from: salt, EDTA, sorbitol, sugar, flavoring agent.
- This is an “optional add-in” limitation; a product having such components can satisfy claim 14 if it otherwise meets claim 1.

Claim 15/16: intranasal spray and “two sprays”

Claim 15: intranasal administration comprises an intranasal spray.
Claim 16: administered as two sprays.
- Device and dosing regimen constraints are relevant for practical labeling and product form. A competitor using drops, atomizer, or a different number of actuations is a common design-around lever.

Claim 17: patient is human

Dependent claim; typically not a major design-around issue.

What is the effective claim “center of mass” around citrate concentration ≥10 mM and delivered dose ~15 mg?

Core answer: Claim 1’s discriminators are the dose-about-15 mg and citrate ≥10 mM while using intranasal administration to treat gastroparesis.

Why citrate matters legally

Citrate is explicitly required as a concentration-based excipient in the independent claim.
Many intranasal formulations use different buffering salts (phosphate, acetate) and different ionic conditions. Claim 1 is aimed at a specific formulation family.

Dose anchor effects

“about 15 mg” is a dosing boundary rather than a pure per-spray number.
Still, competitors typically must match the overall delivered dose to reproduce the method limitation.

Likely infringement and invalidity leverage points

Infringement: if a competitor’s product is intranasal metoclopramide for gastroparesis but uses citrate below 10 mM or uses a materially different delivered dose, claim 1 becomes difficult to satisfy.
Invalidity/design-around: prior art that includes intranasal metoclopramide with citrate and a similar dosing concept could impact novelty/non-obviousness for the independent claim. Without the actual specification text and prosecution history, claim construction will hinge on ordinary meaning of “citrate” and how “about 15 mg delivered” is demonstrated experimentally.

How many patents could be involved around this formulation: what to expect in a US Orange Book-style landscape?

Core answer: Based on the claim drafting pattern (intranasal metoclopramide with defined excipient windows and device dosing), the broader US IP landscape typically fragments into: (i) intranasal metoclopramide delivery platform patents, (ii) metoclopramide-use patents for gastroparesis and nausea/emesis, and (iii) formulation/preservative/pH/osmolality patents. However, without the patent bibliographic record, application family, and related patents list for 11,020,361, a quantified count of covering patents cannot be provided here.

What would a generic or reformulated intranasal metoclopramide have to change to avoid US 11,020,361?

Core answer: The main avoidance levers are changing one of claim 1’s anchor parameters: citrate concentration (<10 mM), delivered dose not “about 15 mg”, or route not intranasal, while also considering dependent-claim boundaries on preservative (benzalkonium chloride), benzyl alcohol, pH, and osmolality.

Design-around matrix tied to claim limitations

Claim limitation	Avoidance path	Typical product-change levers
Intranasal route (claim 1)	Use non-intranasal route	Oral, subcutaneous, IV, IM, different administration
Gastroparesis indication (claim 1)	Target different indication	Avoid gastroparesis label/method-of-use steps (still complex)
Metoclopramide dose “about 15 mg” (claim 1)	Deliver different total mg	Re-scale concentration per actuation and number of actuations
Citrate ≥ 10 mM (claim 1)	Use citrate < 10 mM	Switch buffer system (phosphate/acetate), reduce citrate
Benzalkonium chloride 0.005–0.05% (claims 3/4)	Use outside window or remove	Alternative preservative system
pH > about 4.5 (claim 5)	Use pH ≤ 4.5	Buffering and acid/base changes
Benzyl alcohol 0.01–0.8% (claims 6/13)	Remove or change concentration	Alternative antimicrobial/solvent system
Osmolality 500–1400 mOsm/kg (claim 7)	Move osmolality outside window	Ionic strength changes; tonicity agents
Intranasal spray; “two sprays” (claims 15/16)	Use different device/dosing regimen	Drops, different actuation count

How does the claim set allocate risk between “product infringement” and “method-of-use infringement”?

Core answer: The patent is structured as method-of-treatment claims but uses product formulation parameters (citrate concentration, excipient windows, pH, osmolality) and device administration format (spray; two sprays) to define the method. This makes infringement analysis heavily dependent on the defendant’s actual formulation and administration instructions.

Claim construction implications for litigation

A challenger often attacks whether “composition comprises citrate” requires literal citrate as a buffer component versus citrate as a counterion or presence in trace. The claims use “comprises citrate in a concentration of at least about 10 millimolar,” indicating a measurable concentration requirement rather than incidental presence.
“effective to deliver about 15 mg” ties method performance to measurable dose delivery. Competitors will seek evidence on delivered dose versus nominal concentration.

What does this claim structure suggest about prosecution intent (and likely weak points)?

Core answer: The independent claim’s formulation discriminator (citrate ≥10 mM) indicates the applicant likely faced prior art on intranasal metoclopramide or intranasal delivery generally and narrowed to a formulation-and-dose-defined intranasal citrate system for gastroparesis.

Common weak points for such estates, when challenged:

Prior art that already discloses intranasal metoclopramide with citrate at or above the claimed concentration range and similar dosing.
Prior art describing buffers/preservatives/pH/osmolality for intranasal metoclopramide compositions that make dependent claims obvious.
Obviousness arguments that citrate inclusion and tonicity/pH adjustments are routine formulation optimization to stabilize drug and enhance nasal tolerability.

A full strength assessment requires the patent record (specification, priority dates, prosecution history, and cited references), which is not provided in the prompt.

Key Takeaways

US 11,020,361 claim 1 is a method claim that requires intranasal administration of metoclopramide delivering ~15 mg and using a composition with citrate ≥10 mM to treat gastroparesis.
Dependent claims add enforceable product limitations: benzalkonium chloride (0.005–0.05% w/v), pH > 4.5, benzyl alcohol (0.01–0.8% w/v), and osmolality (500–1400 mOsm/kg), plus a closed list of buffer selections and device regimen constraints (spray, two sprays).
The principal design-around levers against claim 1 are citrate concentration, delivered dose, and route. Against dependent claims, preservatives/solvents and physicochemical windows are the main constraints.

FAQs

1) Does US 11,020,361 cover oral or injectable metoclopramide for gastroparesis?
No. The claims require intranasal administration and citrate ≥10 mM in the claimed method framework.

2) If a product uses intranasal metoclopramide for gastroparesis but citrate is 8 mM, is claim 1 avoided?
On the face of the claim, citrate ≥10 mM is a required limitation for claim 1, so moving below that threshold is an immediate avoidance path.

3) Are benzalkonium chloride and benzyl alcohol required for infringement of claim 1?
No. They appear in dependent claims. Claim 1 requires citrate ≥10 mM and ~15 mg delivered intranasally for gastroparesis.

4) Can a different number of intranasal sprays avoid claims 15–16?
Yes. Claims 15–16 add specific administration format constraints, including “two sprays.”

5) What is the most litigation-sensitive phrase in the claim set?
“effective to deliver about 15 mg” and “citrate … at least about 10 millimolar” are the tightest measurable anchors that drive infringement proof.

References (APA)

United States Patent 11,020,361. (n.d.). Method of treating gastroparesis using intranasal metoclopramide with citrate.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2780485	⤷ Start Trial
Canada	2984736	⤷ Start Trial
Canada	3155873	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,020,361

Which drugs does patent 11,020,361 protect, and when does it expire?

Summary for Patent: 11,020,361